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a b s t r a c t
We report a rare case of tuberculosis of the thoracic spine caused by Mycobacterium bovis
infection as a complication of BCG (Bacillus Calmette-Guérin) intravesical immunotherapy,
which is a well known and acknowledged treatment of superﬁcial bladder cancers applied
since 1976. Although this therapy is broadly used in urology and considered to be safe and
well tolerated, one should be aware of the potential local and systemic side effects as in the
case of our patient, who developed tuberculous spondylodiscitis after intravesical BCG
therapy.
# 2015 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Low back pain is one of the main causes of medical
consultations and the ﬁfth most common reason of all
physician visits in the USA [1]. The lifetime prevalence of
spinal pain has been estimated at as high as 54% to 80%
of population and its frequency raises with age [2]. This
most common form of this pain is mainly associated with
mechanical and degenerational changes of various spinal
structures. Nevertheless, in the minority of cases the low back* Corresponding author at: Neurology Department, St. Adalbert Hospi
80-462 Gdańsk, Poland. Tel.: +48 58 768 46 61.
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0028-3843/# 2015 Polish Neurological Society. Published by Elsevier Spain may be a symptom of severe and even life-threatening
disorders, one of them is spondylodiscitis – the inﬂammation
of the vertebral bodies and intervertebral disk space, caused by
various pathogens. Its incidence is estimated at 0.4–2.4/100,000
[3]. Mycobacterium tuberculosis is responsible for even 17–39% of
all the cases of spondylodiscitis [4]. Musculoskeletal tubercu-
losis is generally rare in comparison to other forms of the
disease, but among its cases the spine is the most frequently
affected and accounts for 1–3% of all tuberculous infections [5].
Although in a signiﬁcant percentage of tuberculous
spondylodiscitis the primary infection is not evident, in thetal, Copernicus Podmiot Leczniczy Sp. z o.o., Al. Jana Pawła II 50,
p. z o.o. All rights reserved.
Fig. 1 – A CT scan of the spine with degenerational process
of Th10-11 vertebraes and intervertebral space.
Fig. 2 – T2-weighted MRI scan with the destructive process
of Th10-11 vertebraes and intervertebral space, epidural
abscess and spinal cord compression.
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the mycobacterium from a latent pulmonary focus [6]. It can
spread also by contiguous or lymphatic way [4]. Other possible,
but very rare routes of spreading the bacteria in patients
without primary infection, such as BCG osteomyelitis, are
vaccinations (the risk is one in a million, with very infrequent
spine involvement [7] or intravesical immunotherapy (the
exact prevalence is unknown [8]).
BCG is an attenuated strain of Mycobacterium bovis and its
use is broadly approved in medical practice both as a vaccine
and anticancer agent [9]. Intravesical application of BCG
immunotherapy is an established and effective treatment of
bladder carcinomas and carcinomas in situ (CIS) [10]. It is
considered to be a safe procedure, however sometimes serious
complications may occur. We present a case of a 67-year-old
patient with spondylodiscitis following BCG intravesical
treatment as an example of a very rare, but severely dangerous
side effect of this therapy.
2. Case report
A 67-year-old man was admitted to the neurological ward with
the history of low back pain lasting about six months and a
5 kg weight loss. His past medical history included arterial
hypertension and bladder cancer of papillary type. He
underwent a few transurethral resections of tumor during
10 years after initial diagnosis and the procedure was repeated
due to neoplasm recurrences. In order to prolong time between
the subsequent relapses the patient ﬁnally received a full
cycle of BCG immunotherapy (6 applications administered at
weekly intervals) with 3 additional applications administered
at monthly intervals. One month after the last intravesical
installation he noticed the appearance of low back pain. An
out-patient lumbar radiograph showed the scoliosis of
thoracic and lumbar spine segments with no other signiﬁcant
pathologies. The cytoscopy examination performed 6 months
after ﬁnishing the BCG immunotherapy did not show tumor.
Despite using anti-inﬂammatory and analgesic medications
prescribed by general practitioner the pain was debilitating
and ﬁnally the patient was admitted to hospital. He denied
any trauma, did not have fever, nor night sweats. His basic
blood tests were normal, including white blood cells count, ESR
(erytrocyte sedimentation rate) and CRP (C-reactive protein).
He had no previous history of tuberculosis infection.
Physical examination on admission showed the following
neurological symptoms: mild proximal weakness of lower
limbs and slight hypoaesthesia below the L1 dermatome level,
but he was still able to walk. CT (computed tomography)
showed destruction of T10 and T11 vertebraes with fractures
of terminal laminas, disk interspace involvement and the
formation of the epidural abscess (Fig. 1). MRI (magnetic
resonance imaging) scan of the spine conﬁrmed the destruc-
tion of the T10-11 vertebraes and their interspace (Fig. 2).
Diagnosis of osteomyelitis or metastatic changes was sus-
pected by radiologist.
In the subsequent CT scan of the whole trunk (thorax and
abdomen) neither features of tuberculosis, nor of active
neoplasm or metastatic process were found. The examination
also did not reveal any other sources of inﬂammation. Basedon the preasumptive diagnosis of discitis the neurosurgeons
were requested to perform a biopsy of the involved spine
segment. As they initially refused to perform this procedure, it
resulted in a10-day delay between the admission and surgical
intervention. Due to uncertainty of the diagnosis empirical
treatment was applied (ceftriaxone 2  1 g i.v. and lincomycin
3  600 mg i.v.), as recommended for the discitis.
Fig. 3 – T1 MRI scans after first surgery showing bone block with necrolysis, epidural abscess and spinal cord impression: (A)
sagittal, (B) axial images.
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not show neoplastic cells, but four weeks later the microbio-
logical cultures revealed the acidoresistant bacillus infection,
further reported as M. tuberculosis complex. The therapy was
changed to antimycobacterium treatment. The sensitivity
was tested and showed that the bacterium may response to
rifampicyne, isoniasid, ethambuthol and streptomycin and is
resistant to pyrazinamide (which raised our suspicion that
the strain could be M. bovis, due to the resistance of this
pathogen to that antibiotic, earlier reported in the literature
[9]). Subsequent PCR (polymerase chain reaction) conﬁrmed
that the bacterium was M. bovis BCG strain.
Patient was referred to Polish Referral Center of Treating
Tuberculosis of Bones and Joints in Otwock/Warsaw, where
the surgical intervention was performed. He underwent the
debridement of inﬂammatory changes with decompressionFig. 4 – The X-ray of the spinof the spinal cord. Unfortunately, postoperative recovery was
complicated and several weeks after the procedure the patient
still suffered from severe back pain and the progression
of paraparesis. He was unable to walk or even stand. He
also complained of vision lost. He was again admitted to the
neurological department. The ophthalmological examination
revealed drug related toxic neuropathy, which was conﬁrmed
by VEP (Vision Evoked Potentials). The NCS (nerve conduction
studies) showed features of axonal polineuropathy probably
also due to antituberculosis treatment. The control MRI scan
(Fig. 3) showed the inﬂammatory compression of the thoracic
spine and subsequently the second surgery was performed
with the excision of abscesses and decompression of the
spinal cord (Fig. 4).
Three months after the second surgical procedure the
general condition of the patient improved: the pain relievede after second surgery.
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use of a wheelchair, but recently at the rehabilitation
department he started to stand and walk. He still continues
anti-tuberculosis chemotherapy regimen (isoniazid 300 mg
and rifampicin 600 mg/daily). The ethambutol was discon-
tinued previously due to drug-related toxic neuropathy of
optic nerves.
3. Discussion
M. bovis is a component of the M. tuberculosis complex, which
refers to a genetically related group of Mycobacterium species
that can cause tuberculosis in humans or other organisms. It
includes M. tuberculosis, Mycobacterium africanum, M. bovis and
the Bacillus Calmette-Guérin strain, Mycobacterium microti,
Mycobacterium canettii, Mycobacterium caprae, Mycobacterium
pinnipedii, Mycobacterium mungi [11]. A live attenuated strain
of M. bovis BCG has been used in medicine since 1921 when
it was initially applied as a vaccine in order to prevent
tuberculosis infection [12]. Later, in 1976 Morales et al. [13]
made use of the BCG strain in a new therapeutic approach to
the treatment of superﬁcial bladder neoplasm. It was a
signiﬁcant breakthrough in uro-oncology as the rate of tumor
recurrence was very high (it had occurred in approximately
88% of patients) and BCG immunotherapy reduced it on
average by about 40%, which also led to a decrease in mortality
[14]. Nowadays BCG is the initial treatment of choice for theTable 1 – The reported cases of spinal M. bovis infection follow
modified and supplemented).





Obaid et al. [10] 67, M 11 m L1/L2 LBP, right leg
weakness
Katz et al. [21] 67, M 16 m L4/L5 LBP, anorexia
L5 & S1
radiculopath
Abu-Nader [9] 76, M 7 y T6/T7 LBP, anorexia
parentheses 




77, M 0.5 m T11/L1 LBP, kyphosis
Nikaido et al. [12] 86, M 2 y T12/L1 LBP 
Samadian et al. [24] 94, M 5 m L1/L2 LBP, malaise 
Colebatch et al. [25] 67, M 2 y L4/L5 LBP 
Civen et al. [26] 81, M 7 m T12/L1 LBP, weight l
Fishman et al. [27] 90, M 1 m T11/T12 LBP 
Patel et al. [28] 66, M 5 m T10/T11 LBP 
Mavrogenis et al. [29] 72, M 11 y L3/L4 LBP, anorexia
radiculopath
Rozenblit et al. [30] 76, M 6 y L4 LBP, right leg
weight loss
Dahl [31] 69, M 1 y L3/L4 LBP 
Newman [20] 80, M 3 y T9/T10 Fatigue, weig
Santbergen [8] 58, M 3 y T8/T9 LBP 
Sugita et al. [32] 71, M 2 m T7 LBP 
Josephson et al. [33] 75, M 6 m L1/L2 LBP, fatigue 
LBP, low back pain; m, moths; y, years.carcinoma in situ and it is still used as a main adjunctive
therapy after surgical resection of tumor [10,15]. The standard
induction schedule consists of 6 intravesical installations
administered at weekly intervals [13]. BCG therapy stimulates
the local immune system and cell-mediated activity plays a
major role in this response, which results in the inﬂammation
and eradication of tumor cells [16]. This treatment is generally
considered safe and in >95% of patients it is well tolerated [14].
However, unpleasant side effects due to the inﬂammatory
reaction are relatively common. The patients often experience
irritative bladder symptoms (urgency, dysuria, frequency of
voiding) accompanied by low-grade fever and malaise for less
than 24–48 h after installation [17,18]. This phenomenon is
not regarded as an adverse event, it is rather treated as a
marker for adequate anticancer effect exerted by the BCG [19].
Nevertheless, other infrequent extravesical and systemic
complications may also occur such as: fever (2.9%), hematuria
(1%), prostatitis (0.9%), urethral obstruction (0.3%), renal
abscess, granulomatosus involvement of various organs and
the most dangerous of them – systemic septic reaction with
the incidence of 0.4% [14]. Another possibly fatal side effect is
tuberculous spondylodiscitis, which seems to be an excep-
tionally rare complication, accordingly to the paper of New-
man [20] only 15 previous cases had been described in the
literature till 2014. This list can be supplemented by 3 new
cases recently published. All published reports are summa-
rized in Table 1. In contrast to the frequency of this therapy
worldwide, it seems to be a rather low number.ing BCG intravesical therapy (according to Obaid et al. [10]
esentation Surgery Outcome
 mild + Complete recovery
, right
y
+ No long term follow-up
, bilateral
& paraparesis
 percutaneous biopsy Improvement of
symptoms
pain, left + After 1 year still
leg weakness
 + Functional after 1 year
 percutaneous biopsy Complete recovery
 percutaneous biopsy No long term follow-up
 percutaneous biopsy No long term follow up
oss + Complete recovery.
+ (open biopsy) Not speciﬁed




+ Remission of pain
at 18 months
 pain,  percutaneous biopsy Asymptomatic at
8 months.
+ Complete recovery
ht loss + Unknown
 percutaneous biopsy Complete recovery
+ Not speciﬁed
 percutaneous biopsy No long term follow-up
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probable way of bacteria's dissemination after the procedure.
This hypothesis can be supported by observations that M. bovis
was identiﬁed in all the previously reported cases [10] (and also
in our patient) and indirectly supported by the published cases
of the large vessel mycotic vasculitides following BCG bladder
[8,34]. The possible risk factors have been associated with
this way of dissemination: the injury of the bladder during
catheterization, deep tumor resection, urethral trauma during
BCG installation, outer obstruction of bladder, previous pelvic
radiation, transurethral prostate resection or bladder biopsy
within 2 weeks before starting BCG therapy and all immuno-
comprised states [9,10] It was also reported that sometimes
bacilli may persist in the urinary tract for over one year
following the treatment [35]. It may explain why some patients
remain at risk of disseminated infection for many months
and even years after BCG therapy as in the case reported by
Mavrogenis et al. in which the reactivation appeared 12 years
after the initial treatment [29]. The genetic factors predispos-
ing to those complications may be related to a deletion in the
gene encoding interferon gamma or interleukin 12 receptor
which can be responsible for the decreased host defense
against mycobacterial infections [36].
Diagnosis of the tuberculous spondylodiscitis is often
delayed or even missed [37]. The time between the onset of
symptoms and ﬁnal diagnosis ranges from 2 months to 4 years
[4]. The disease onset is often insidious, tuberculous spondy-
lodiscitis has much slower and less painful clinical evolution
in comparison to pyogenic infections. It is due to microbiolog-
ical characteristic of mycobacterium which grows slowly and
does not present proteolitic enzymes activity. Fever is often
absent (was reported in less than 40% of cases) and was not
reported in our case either [4]. The most common clinical
symptom reported in many studies is the back pain (more than
80% of patients) [37]. As it is a very common complaint,
especially in older population, it may be missed. Regardless
the inﬂammatory response, laboratory studies may not be
helpful in differential diagnosis. CRP and white blood cells
levels as in our case are usually normal in the majority cases
[38]. ESR values are often found to be elevated [4], although
in the case of our patient it was low, too. Among non-invasive
studies, radiological methods are essential for diagnosis
and management of the spine tuberculosis [39,40]. The
major radiological ﬁndings reported by Maeda et al. were:
osteolityc changes (86%), narrowing of disk space (73%), loss
of vertebral body height (69%), erosion of the vertebral
endplates (56%) [41].
Nevertheless, although MRI features are highly supportive
in diagnosing skeletal tuberculosis, they are not pathogno-
monic [42] and require an active search for other sites
potentially infected by mycobacteria and further differential
diagnosing. Typically tuberculous spondylodiscitis affects
the thoraco-lumbar hinge of the spine [43], which was also
conﬁrmed in our case.
In all the cases of the discitis and especially in those
suspected of tuberculous spondylodiscitis, biopsy and patho-
gen isolation is the method of choice [4,44]. This procedure
should be mandatory in all possible cases as it allows to ﬁnd
a speciﬁc pathogen and test antimicrobial sensitivity what
results in an appropriate treatment [4]. In the case of ourpatient the microbiological diagnosis obtained from the biopsy
specimen totally has changed the therapeutical approach. The
increasing incidence of MDR TBC (multidrug-resistant tuber-
culosis) reported in many countries may encourage this
approach [45]. It seems also important to distinguish M. bovis
BCG from M. tuberculosis. This cannot be obtained by
microscopic evaluation. Only sophisticated molecular meth-
ods may discern members of Mycobacterium complex, such as
different PCR modiﬁcations with restriction enzymes analyses
or gene sequencing [33].
The osteoarticular infections caused by BCG should be
treated by standard triple-regimen anti-tuberculous therapy
[46], with the exception of pyrazinamide because M. bovis
strains are resistant to this drug [9,15,47]. It is a characteristic
feature of this bacterium and can be an important diagnostic
clue (as it was also in our patient). Hence, isoniazid and
rifampicin with ethambutol should be used as ﬁrst-line
antibiotics for BCG infections for two months, then followed
by isoniasid and rifampicin for the next 10 months [48].
Ethambutol may rarely complicate this treatment and cause
severe optic nerve neuropathy leading even to the loss of
vision [49]. Therefore, all patients undergoing the treatment
should be monitored ophthalmologically. The early withdraw-
al of the antibiotic potentially allows for the recovery of vision
[50], as it was shown in our patient. In tuberculous spondy-
lodiscitis corticosteroids may also be added [48] to reduce
the spinal cord compression. Our patient also underwent
surgical intervention, which is considered to be necessary in
almost all cases accompanied by either spinal instability or
abscess formation [8,9,29]. The aim of the surgery is a radical
debridement, decompression of the spinal cord and recon-
struction of spinal stability [51].
In conclusion, the back pain following the BCG immuno-
therapy of bladder cancer, irrespective of the time interval
between the onset of symptoms and last application should be
suspected of spondylodiscitis. MRI followed by biopsy are the
methods of choice to make a correct diagnosis and apply a
proper treatment. Although the therapy is of long duration
with possible complications, it may result in signiﬁcant
recovery. To avoid the irreversible spinal cord injury the
diagnosis should be made as soon as possible.
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